What Documented Reports Reveal About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Legal Accountability

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering whether these symptoms point to gastroparesis. Decades of pharmacovigilance research have established a framework for evaluating such adverse events, and this page distills what current reports and clinical signals indicate about the link between Ozempic and gastroparesis.

Ozempic and Gastroparesis: The Medical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain, which overlap with common Ozempic side effects. Diagnosis typically involves gastric emptying scintigraphy or breath testing to confirm delayed emptying. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which may include symptoms consistent with gastroparesis.

Mechanism and Risk Context

The mechanistic pathway linking Ozempic to gastroparesis involves GLP-1 receptor activation in the gastrointestinal tract, which slows gastric motility. This effect is part of the drug's intended action to reduce postprandial glucose excursions, but in some patients, it may become pathological, leading to symptomatic delayed gastric emptying. The timeline between exposure and documented harm varies; gastrointestinal symptoms often emerge during dose escalation, as noted in clinical trials, but persistent gastroparesis may develop after prolonged use. The FDA label does not explicitly list gastroparesis as a warning, but the high incidence of gastrointestinal adverse reactions suggests a potential risk. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported with Ozempic and other GLP-1 receptor agonists, but these are distinct from gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Regarding the adequacy of warnings, the Ozempic label includes gastrointestinal adverse reactions in the prescribing information, but does not specifically warn about gastroparesis. Patients may not be adequately informed about the risk of developing this condition, which can lead to significant morbidity, including malnutrition, weight loss, and hospitalization.

Virginia Statute of Limitations for Ozempic Claims

For affected patients in Virginia, attorney-related considerations include the statute of limitations for product liability claims. In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or discovery of the injury. For claims involving defective drugs, the timeline may be extended if the injury was not immediately apparent. Patients who developed gastroparesis after using Ozempic should consult with an attorney to determine the applicable deadline based on their specific circumstances, including the date of first use, onset of symptoms, and diagnosis. The timeline between exposure and documented harm is critical for legal claims. Gastrointestinal symptoms often appear within weeks to months of starting Ozempic, but gastroparesis may be diagnosed later after persistent symptoms. Medical records documenting the onset of symptoms, diagnosis, and correlation with Ozempic use are essential. Patients should retain all prescription records, pharmacy receipts, and medical notes to establish the link between the drug and the condition. An attorney can help evaluate whether the manufacturer provided adequate warnings and whether the patient's injury falls within the statute of limitations.

Legal Considerations and Next Steps

In summary, Ozempic use is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's label does not specifically warn about gastroparesis, which may affect the adequacy of warnings. Patients in Virginia who develop gastroparesis after using Ozempic should be aware of the two-year statute of limitations for personal injury claims and seek legal advice promptly. The evidence from clinical trials supports a dose-dependent increase in gastrointestinal events, and the mechanistic link through delayed gastric emptying is plausible. Legal considerations should focus on the timeline of exposure, diagnosis, and the manufacturer's duty to warn. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Virginia?

In Virginia, the statute of limitations for personal injury claims, including product liability claims related to Ozempic, is generally two years from the date of injury or discovery of the injury. For claims involving defective drugs, the timeline may be extended if the injury was not immediately apparent. It is crucial to consult with an attorney promptly to determine the applicable deadline based on your specific circumstances.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism to reduce postprandial glucose. In some patients, this effect becomes pathological, leading to symptomatic delayed gastric emptying consistent with gastroparesis. Clinical trials show a dose-dependent increase in gastrointestinal adverse events, including nausea, vomiting, and dyspepsia, which may indicate gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What evidence do I need for an Ozempic gastroparesis lawsuit?

You will need medical records documenting the diagnosis of gastroparesis (e.g., gastric emptying scintigraphy), prescription records showing Ozempic use, pharmacy receipts, and medical notes linking the onset of symptoms to Ozempic. Retaining all documentation of your treatment timeline is essential to establish the causal link and meet the statute of limitations.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.